2013 NLA Scientific Sessions Highlights

Peter P. Toth, MD, PhD, presented the National Lipid Association's HDL Consensus Statement that is set to be published in the Journal of Clinical Lipidology in the November/December issue.

Don P. Wilson, MD, presented that over the past three decades it has become evident that atherosclerosis has its origins in childhood. Children and adolescents with genetic and/or acquired CVD risk factors can be easily identified. When present at a young age, these risk factors track into adulthood and have been associated with moderate-to-high risk of future cardiovascular disease.

Paul Gurbel, MD, presented that dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor blocker is a key strategy in patients with high risk coronary artery disease patients to reduce platelet reactivity and subsequent thrombotic cardiovascular event occurrence. High on-treatment platelet reactivity to adenosine diphosphate (HPR) is a strong risk factor for post-PCI ischemic event occurrence.

Paul Ridker, MD presented the history behind the JUPITER trial and their hypothesis which evaluated whether or not statin therapy would reduce the risk of type-II diabetes in a primary prevention population.